Procedure
Hypertonic Saline + Chest Percussion for Bronchiolitis
This trial will test if using a combination of nebulized hypertonic saline and chest percussion therapy is effective in treating babies and toddlers with acute bronchiolitis. Patients aged 0 to 24
Popular Filters
Trials for BOS Patients
Janus Kinase Inhibitor
Ruxolitinib for Lung Dysfunction Post Stem Cell Transplant
This trial is testing whether a new combination of drugs can help treat a common and serious side effect of a stem cell transplant that often leads to long-term problems or even death.
Immunosuppressant
LAM-001 for Bronchiolitis Obliterans Syndrome
This trial will investigate the safety and effectiveness of inhaled sirolimus to slow bronchiolitis obliterans syndrome (BOS) progression in lung transplant recipients. Participants will be randomly assigned to inhale sirolimus or placebo for 48 weeks and attend 10 visits.
Immunomodulator
ARINA-1 for Bronchiolitis Obliterans Syndrome
This trial is testing ARINA-1, a new treatment added to usual care, for lung transplant patients at risk of a serious lung condition called BOS. The goal is to see if ARINA-1 can prevent the condition from getting worse and improve patients' quality of life. The trial involves periodic health monitoring to track progress and any side effects.
Neutrophil Elastase Inhibitor
Alvelestat for Bronchiolitis Obliterans Syndrome
This trial is testing a new drug, alvelestat (MPH966), to see if it's safe and effective in treating bronchiolitis obliterans syndrome (BOS). BOS is a complication people can experience after hematopoietic stem cell transplant.
Procedure
Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome
This trial is studying how well Extracorporeal Photopheresis works in treating patients with either refractory or newly diagnosed Bronchiolitis Obliterans Syndrome after lung transplantation.
Trials for Bronchiolitis Obliterans Patients
Janus Kinase (JAK) Inhibitor
Continued Itacitinib Treatment for Myelofibrosis
This trial provides the medication itacitinib to participants from previous studies who may benefit from continued treatment. Itacitinib helps reduce inflammation by blocking specific proteins that cause it.
Phase 3 Trials
Immunomodulator
ARINA-1 for Bronchiolitis Obliterans Syndrome
This trial is testing ARINA-1, a new treatment added to usual care, for lung transplant patients at risk of a serious lung condition called BOS. The goal is to see if ARINA-1 can prevent the condition from getting worse and improve patients' quality of life. The trial involves periodic health monitoring to track progress and any side effects.
Procedure
Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome
This trial is studying how well Extracorporeal Photopheresis works in treating patients with either refractory or newly diagnosed Bronchiolitis Obliterans Syndrome after lung transplantation.
Trials With No Placebo
Procedure
NAVA vs Standard Ventilation for Bronchiolitis
This trial aims to find out if using a special mode of non-invasive ventilation called Neurally-Adjusted Ventilatory Assistance (NAVA) can improve comfort and reduce the need for more intensive treatment
CDS + HHFNC Weaning for Bronchiolitis
This trial aims to improve recovery from common pediatric respiratory illnesses, reduce costs, and show UPMC Children's Hospital's capabilities in pediatric healthcare. It will examine using CDS to improve adherence to standardized guidelines and outcomes.
Behavioral Intervention
Clinical Pathway Intervention for Pediatric Respiratory Conditions
This trial tests a new way to help doctors treat children with asthma, pneumonia, or bronchiolitis in community hospitals. The method uses simple visual guides to ensure doctors follow the best care practices. The goal is to improve health outcomes and reduce hospital stays and costs.
Janus Kinase Inhibitor
Ruxolitinib for Lung Dysfunction Post Stem Cell Transplant
This trial is testing whether a new combination of drugs can help treat a common and serious side effect of a stem cell transplant that often leads to long-term problems or even death.
Frequently Asked Questions
Introduction to bronchiolitis
What are the top hospitals conducting bronchiolitis research?
Bronchiolitis, a common respiratory infection affecting infants and young children, has prompted several leading hospitals to undertake clinical trials in search of improved treatments. Among these institutions is the esteemed Cleveland Clinic in Cleveland, which currently has six active bronchiolitis trials underway, building upon its earlier accomplishment of eight completed studies since recording its first trial in 2008. Meanwhile, Baylor University Medical Center in Dallas is making noteworthy strides with four ongoing bronchiolitis trials, marking their involvement and commitment since initiating their initial trial back in 2015.
In Houston's medical landscape lies Houston Methodist Hospital—a facility that recognizes the importance of combating bronchiolitis through research. This hospital currently conducts four active clinical trials for this condition while maintaining an equal number of previously held investigations. Their journey began just two years ago with their inaugural bronchiolitis trial in 2019. Similarly dedicated to advancing knowledge about this troubling illness is Banner Health located in Phoenix; they too are actively involved with three current bronchiolitis studies and have contributed to our understanding by undertaking three previous investigations starting from 2019 as well.
Last but not least on this list stands Stanford University Hospital situated amidst Palo Alto's renowned medical community. Despite having only started recording data on bronchiolitis clinical trials a couple of years ago—just like Hospital #3 and #4—they are already conducting three active studies for the condition while having accomplished an equivalent number thus far.
Research conducted at these top-tier hospitals signifies significant progress towards improving outcomes for those affected by bronchiolitis, particularly vulnerable infants and children who bear the brunt of this respiratory infection's impact. The dedication displayed by these institutions underscores their commitment to pioneering innovative treatments and potentially revolutionizing care for countless young patients worldwide facing this challenging condition.
Which are the best cities for bronchiolitis clinical trials?
When it comes to bronchiolitis clinical trials, several cities emerge as key hubs for research. Philadelphia, Pennsylvania leads the way with 11 active trials investigating treatments like itacitinib and Liposomal Cyclosporine A. Houston, Texas and Boston, Massachusetts closely follow with 9 ongoing studies each focused on interventions such as Audit & Feedback (unit level) and Cohort A: Belumosudil + Standard of Care Medications. Columbus, Ohio and Dallas, Texas also contribute to the advancement of bronchiolitis care through their ongoing trials exploring various treatments including ARINA-1 plus standard of care. These cities provide individuals affected by bronchiolitis access to cutting-edge clinical trials that pave the way for improved treatment options in the future.
Which are the top treatments for bronchiolitis being explored in clinical trials?
Exciting advancements are underway in the exploration of treatments for bronchiolitis, with two standout contenders leading the way in current clinical trials. Liposomal Cyclosporine A, introduced in 2019, has shown promise and is currently being tested in two ongoing trials specifically for bronchiolitis. Similarly, Itacitinib, making its debut in 2020, is also being investigated through two active trials dedicated to this respiratory condition. As researchers delve deeper into these potential therapies and gather valuable data from their studies, there is hope that new avenues for managing bronchiolitis will soon be within reach.
What are the most recent clinical trials for bronchiolitis?
Recent clinical trials for bronchiolitis have shown promising developments in the field of treatment. Sirolimus, a drug currently undergoing Phase 2 trials, holds potential as a therapeutic option for this respiratory condition. In addition, the ARINA-1 trial is evaluating the efficacy of ARINA-1 combined with standard care in Phase 3 studies. Another notable study investigated Ruxolitinib's effectiveness and safety in treating bronchiolitis during its Phase 2 stage. Additionally, magnesium sulfate has undergone both Phase 2 and Phase 3 trials to assess its impact on bronchiolitis management. Lastly, Itacitinib is being evaluated through a Phase 1 trial to determine its feasibility as a treatment option for bronchiolitis patients. These ongoing investigations bring hope for improved outcomes and better quality of life for individuals affected by this condition.
What bronchiolitis clinical trials were recently completed?
Stanford University recently completed a clinical trial investigating the potential of Pirfenidone 267 MG [Esbriet] in treating bronchiolitis. This significant milestone marks an important step towards improved treatments for this respiratory condition.